Recently, SCN9A gene which encodes for NaV1.7 voltage-gated sodium channel, has been linked to molecular pathophysiologies of pain disorders like inherited erythromelalgia and inherited paroxysmal extreme pain disorder (PEPD) and has emerged as a therapeutic target for treatment of neuropathic pain [8] Additionally, nearly 20 disorders affecting skeletal muscle contraction, cardiac rhythm, or neuronal function have been linked to these mutations in human. This evidence concerns the gene SCN9A and paroxysmal extreme pain disorder.